SOPHiA Genetics, Myriad team up to advance prostate cancer genomic instability score technology
Bitget2026/10/08 13:01SOPHiA GENETICS entered a collaboration with Myriad to advance a prostate cancer genomic instability score for AstraZeneca precision oncology trials. Deal targets development of PrGIS, an HRD-related biomarker signature, for use in clinical trials and potential companion diagnostics. SOPHiA GENETICS will integrate PrGIS into its Extended Homologous Recombination Solution to support decentralized testing across its global lab network. Myriad’s MyChoice CDx test will generate the PrGIS score, with development underway to add prostate cancer as a new indication. Myriad plans to present PrGIS research co-authored with AstraZeneca at the ESMO Congress 2026, pending embargo. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via CNW (Ref. ID: 202610080900CANADANWCANADAPR_C8579) on October 08, 2026, and is solely responsible for the information contained therein.
- SOPHiA GENETICS entered a collaboration with Myriad to advance a prostate cancer genomic instability score for AstraZeneca precision oncology trials.
- Deal targets development of PrGIS, an HRD-related biomarker signature, for use in clinical trials and potential companion diagnostics.
- SOPHiA GENETICS will integrate PrGIS into its Extended Homologous Recombination Solution to support decentralized testing across its global lab network.
- Myriad’s MyChoice CDx test will generate the PrGIS score, with development underway to add prostate cancer as a new indication.
- Myriad plans to present PrGIS research co-authored with AstraZeneca at the ESMO Congress 2026, pending embargo.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Crypto prices
More
